Predictive capabilities of the Gastrointestinal Symptom Rating Scale in the eradication of Helicobacter pylori in patients with type 2 diabetes mellitus
Abstract
The study aimed to determine the predictive capabilities of the Gastrointestinal Symptom Rating Scale (GSRS) for assessing the effectiveness of eradication therapy in Helicobacter pylori (HP) infected patients with type 2 diabetes mellitus. The study involved 60 patients of both sexes with a diagnosis of type 2 diabetes mellitus and chronic HP-associated gastritis, the average age of patients was 61.9 years, average duration of type 2 diabetes was 10.1 years. For statistical analysis of the data, we used the method of constructing ROC curves, which allowed us to identify prognostic factors (in this case, gastroenterological syndromes, such as abdominal pain, reflux, indigestion, diarrhea and constipation) that influence the effectiveness of eradication therapy in patients with type 2 diabetes. It was found that high values of reflux and indigestion syndromes scales of the GSRS are associated with the probability of low eradication therapy response in patients with type 2 diabetes, i.e. these syndromes can act as complicating factors for the elimination of Helicobacter pylori. The obtained data suggest the need for screening diagnostics of Helicobacter pylori, clinical manifestations of gastrointestinal pathology and subsequent etiological and pathogenetic treatment.
About the Authors
A. E. ShklyaevRussian Federation
Shklyaev Aleksey E. — Dr. Sci. (Med.), Professor, Department of Faculty Therapy with Courses of Endocrinology and Hematology
Izhevsk
D. D. Kazarin
Russian Federation
Kazarin Daniil D.— Assistant, Department of Faculty Therapy with Courses of Endocrinology and Hematology
281, Kommunarov str., Izhevsk, 426034
Yu. V. Gorbunov
Russian Federation
Gorbunov Yuri V. — Dr. Sci. (Med.), Professor, Head, Department of Faculty Therapy with Courses of Endocrinology and Hematology
Izhevsk
References
1. Brashchenkova A.V. (2008). Features of the clinical course of type 2 diabetes mellitus in patients with nonalcoholic steatohepatitis. Cand. Sci. (Med.) Theses: 14.00.03, 14.00.05. St. Petersburg, 21 p. In Russ.
2. Dedov I.I., Shestakova M.V. (eds.) (2016). Diabetes Mellitus Type 2: From Theory to Practice. Moscow: Medinformagentstvo, 576 p. In Russ.
3. Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Dedov I.I. (2019). Diabetes epidemiology in Russia: What has changed over the decade? Therapeutic Archive, 91 (10), 4–13.
4. Kolokolov O.V. (2017). Damage to the nervous system in diabetes mellitus: a neurologist’s point of view. Lechaschi Vrach Journal, 7, 65. In Russ.
5. Demicheva T.P., Smirnova E.N., Trushnikova M.V. (2019). Features of microcirculatory disorders in patients with type 2 diabetes mellitus (p. 254). In Personalized medicine and practical health care: VIII (XXVI) Nat. Congress of Endocrinologists with international participation. Abstr. Moscow. In Russ.
6. Shulpekova Yu.O. (2011). Gastroenterological manifestations of autonomic diabetic neuropathy. Rus. Med. Journal, 17, 96–101. In Russ.
7. Fedorchenko Yu.L., Korneeva N.V. (2010). Influence of insulin therapy on the course of gastroesophageal reflux disease in type 2 diabetes mellitus. Experimental and Clinical Gastroenterology Journal, 11, 35–39. In Russ.
8. Kudabaeva Kh.I., Kushimova D.I., Bazargaliev E.Sh. (2012). Features of the course of chronic gastritis in type 2 diabetes mellitus. Bulletin of the Club of Pancreatologists, 14, 52–54. In Russ.
9. Trukhan D.I., Tarasova L.V., Trukhan L.Yu. (2013). Gastroenterological disorders in patients with diabetes mellitus. Journal of Family Medicine, 8, 51–59.
10. Martynyuk M.V. (2018). Comparative analysis of various treatment regimens of anti-Helicobacter pylori therapy in patients with chronic gastroduodenal diseases in combination with type 2 diabetes mellitus. Cand. Sci. (Med.) Theses: 14.01.04. Khabarovsk, 178 p. In Russ.
11. Gasbarrini А., Ojetti V., Pitocco D. (2000). Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand. J. Gastroenterol., 35 (3), 260–263.
12. Mkrtumyan A.M., Kazyulin A.N., Bairova K.I. (2010). Incidence and graveness of Helicobacter infection in patients with type 2 diabetes mellitus. Diabetes Mellitus, 1, 77–79. In Russ.
13. Wiklund I., Bardhan K.D., Müller-Lissner S. (1998). Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital. J. Gastroenterol. Hepatol., 30 (1), 19–27.
14. Redkin A.N., Chukardin A.V., Brykalina Yu.V. (2009). Validation questionnaire GSRS for studying quality of a life at the patients who have transferred abdominal surgical interventions. System Analysis and Management in Biomed. Systems, 8 (1), 98–100.
15. Shklyaev A.E., Gorbunov Y.V. (2016). The use of specific and non-specific questionnaires to assess the quality of life of patients with functional disorder of intestine. The Russian Archives of Internal Medicine, 6, (4), 53–57.
16. Novik A.A., Ionova T.I. (2012). Guidelines for the Study of the Quality of Life in Medicine. 3rd ed., revised. Moscow: Publishing house of the Russian Academy of Natural Sciences, 528 p.
17. Grigoriev S.G., Lobzin Yu.V., Skripchenko N.V. (2016). The role and place of logistic regression and ROC analysis in solving medical diagnostic task. Journal Infectology, 8, (4), 36–45.
18. Shklyaev A.E., Kazarin D.D., Gorbunov Y.V. (2020). Efficacy of prokinetic itopride in type 2 diabetes mellitus. Experimental and Clinical Gastroenterology Journal, 181 (9), 35–39. doi: 10.31146/1682-8658-ecg-181-9-35-39.
Review
For citations:
Shklyaev A.E., Kazarin D.D., Gorbunov Yu.V. Predictive capabilities of the Gastrointestinal Symptom Rating Scale in the eradication of Helicobacter pylori in patients with type 2 diabetes mellitus. Journal of Siberian Medical Sciences. 2021;(2):49-55. (In Russ.)